Bolt Biotherapeutics, Inc. (BOLT) financial statements and ratios from SEC XBRL: revenue $7.70M (TTM), net margin -433.7%, revenue growth -99.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $7.70M |
| Net Margin | -433.7% |
| Revenue Growth (YoY) | -99.7% |
| EPS Growth (YoY) | 2.5% |
| FCF Growth (YoY) | -31.7% |
| Price / Book | 0.57 |
| Price / Sales | 1.53 |
| FCF Yield | -227.6% |
| Altman Z-Score | -12.73 (distress) |
| Sector P/E (Healthcare) | 21.7 |
BOLT overview · BOLT earnings · BOLT KPIs · BOLT investor relations · BOLT ownership · BOLT peers · BOLT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.